Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TOVX with free AI briefings, catalyst countdowns, and dilution alerts.

TOVX · Theriva Biologics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.5M Cash on Hand
8.6mo Cash Runway
Follow TOVX by email Get an email when TOVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TOVX, unsubscribe in one click. Privacy

📣 What TOVX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Period 1 - Treatment Sequence AC Healthy Volunteers Phase 1/2 · NCT02419001 Completed
Zabilugene Almadenorepvec (VCN-01) Pancreas Cancer, Metastatic Phase 1/2 · NCT07701486 Recruiting
SYN-010 Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2 · NCT02493036 Completed
Ribaxamase (SYN-004) Clostridium Difficile Phase 2 · NCT02563106 Completed
Period 1 - Treatment Sequence AB Healthy Volunteers Phase 1/2 · NCT02419001 Completed
Nab-paclitaxel Pancreas Cancer, Metastatic Phase 1/2 · NCT07701486 Recruiting
Esomeprazole Healthy Volunteers With Ileostomy Phase 1/2 · NCT02473640 Completed
Ceftriaxone Healthy Volunteers With Ileostomy Phase 1/2 · NCT02473640 Completed
huCART-meso Cells Pancreatic Cancer Phase 1 · NCT05057715 Terminated
Intestinal-Type Alkaline Phosphatase Enteritis Caused by Radiation (Disorder) Phase 1 · NCT04815993 Completed

Also used in these trials (approved or third-party drugs, not TOVX's own candidates): Lovastatin, Gemcitabine Hydrochloride, Paclitaxel, Durvalumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TOVX holds $8.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 8.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TOVX files for a raise →

Get the full TOVX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TOVX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.